Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 3/20 | 0.57 |
| ▸ | SYK | P43405 | 14/20 | 0.51 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | ITK | Q08881 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12765469 | 0.95 | GLO1 (0.60) | GLO1SYKMETALKEGFR | |
| SCHEMBL12765437 | 0.86 | GLO1 (0.68) | GLO1SYKMETALKEGFR | |
| SCHEMBL1040153 | 0.86 | ALK (0.63) | GLO1METALKEGFR | |
| SCHEMBL13695177 | 0.86 | SYK (0.61) | SYK | |
| Hydrochloric Acid SCHEMBL1037398 | 0.86 | GLO1 (0.67) | GLO1SYKMETALKEGFR | |
| SCHEMBL1035671 | 0.85 | GLO1 (0.61) | GLO1SYKMETALKEGFR | |
| SCHEMBL1038887 | 0.85 | SYK (0.72) | GLO1SYKMETALKEGFR | |
| SCHEMBL1038726 | 0.84 | GLO1 (0.61) | GLO1SYKMETALK | |
| SCHEMBL1036264 | 0.83 | GLO1 (0.53) | GLO1SYKMETALKEGFR | |
| SCHEMBL10020816 | 0.81 | GLO1 (0.67) | GLO1SYKMETALKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | claimed |
| EP-2276747-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2011-01-26 | — | — | EP | claimed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | claimed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| EP-2276747-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | ZAP70, SYK, LCK | GLO1 3741/4885SYK 2/4885MET 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.